跳至主要内容
临床试验/NCT05126030
NCT05126030进行中(未招募)不适用

TRiCares Topaz Transfemoral Tricuspid Heart Valve Replacement System First in Human Trial

TRiCares20 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2022年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
TRiCares
入组人数
20
试验地点
20
主要终点
Hierarchical composite endpoint

研究概览

简要总结

The objective of this first in human study is to gain early clinical insight into the safety profile and performance of the Topaz transcatheter tricuspid valve replacement (TTVR) system intended for transfemoral access to deliver a self-expanding bioprosthetic valve within the tricuspid valve.

详细描述

The TRiCares Topaz Prosthesis is intended to replace a diseased tricuspid heart valve via a transcatheter approach without removing the native valve.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject of age >18 years.
  • Subject with severe symptomatic tricuspid regurgitation presenting following conditions:
  • TR severity of at least 3 (severe) on a scale of 0 (none) to 5 (torrential), assessed by independent core lab and/or
  • symptoms requiring use of diuretics.
  • Subject presenting with New York Heart Association Class NYHA ≥II.
  • Subject is not eligible for open tricuspid valve surgery due to high operative risk, as determined by a Heart Team decision.

排除标准

  • Subject in need of emergent or urgent intervention or any planned cardiac intervention within the next 12 months.
  • Subject undergoing cardiac interventions within 30 days prior to index procedure.
  • Subject with concomitant clinically relevant mitral, aortic, pulmonary regurgitation/stenosis.
  • Subject who had previous tricuspid valve replacement or repair and a device is still in situ.

结局指标

主要结局

Hierarchical composite endpoint

时间窗: 30 days

including all-cause mortality, re-hospitalization for heart failure, re-intervention for failed tricuspid intervention, and KCCQ worsening at 30 days

次要结局

未报告次要终点

研究者

发起方
TRiCares
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验